Tony Coles is executive chairman and CEO of Cerevel Therapeutics, a Bain-portfolio biotechnology company specializing in the development of new therapies for diseases of the central nervous system. Coles is a founding investor and the chairman of Yumanity Therapeutics, a biotechnology company focused on transforming drug discovery for neurodegenerative diseases.

Previously, Coles was chair and chief executive officer of Onyx Pharmaceuticals, Inc. Prior to joining Onyx in 2008, he was president, chief executive officer, and a member of the board of directors of NPS Pharmaceuticals, Inc.

Coles currently serves on the boards of directors of McKesson Corporation and Regeneron. Coles is also a member of the council for the Smithsonian’s National Museum of African American History and Culture in Washington, DC, the board of trustees for the Metropolitan Museum of Art in New York City, and the Harvard Medical School advisory board.

Coles earned an undergraduate degree from Johns Hopkins University, a medical degree from Duke University, and a master’s degree from Harvard University. He completed his cardiology and internal medicine training at Massachusetts General Hospital and was a research fellow at Harvard Medical School.